Factors Influencing Fluoroquinolone Resistance [3]

Emerging Infectious Diseases

Volumn 9, Issue 12, 2003, Pages 1651-1654

  Sahm, Daniel F ^a   Thornsberry, Clyde ^a   Jones, Mark E ^a   Karlowsky, James A ^a  

^a Focus Technologies Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; BACTERIUM ISOLATE; CYSTIC FIBROSIS; ENTEROCOCCUS; GENE MUTATION; HOSPITAL INFECTION; HUMAN; INFECTION; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PNEUMONIA; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS PNEUMONIAE;

EID: 0344738833     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0912.030168     Document Type: Letter

References (31)

1. Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 2003;9:1-9.
2. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Evangelista AT, Critchley IA, et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Int J Antimicrob Agents 2002;19:21-31.
3. Blosser-Middleton RS, Sahm D, Evangelista AT, Thornsberry C, Jones ME, Critchley IA, Karlowsky JA. Antimicrobial susceptibilities of common pathogens causing nosocomial pneumonia: 2001-2002 TRUST surveillance. Annual Meeting Infectious Disease Society of America, 2002, abstract 71.
4. Milatovic D, Schmitz F-J, Brisse S, Verhoef, Fluit AC. In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrob Agents Chemother 2000;44:1102-7.
5. Craig WA. Does dose matter? Clin Infect Dis 2001;33(Suppl 3):S233-7.
6. MacGowan AP, Wootton M, Holt HA. The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility. J Antimicrob Chemother 1999;43:345-9.
7. Sahm DF, Thornsberry C, Jones ME, Blosser R, Critchley IA, Evangelista AT, Karlowsky JA. Antimicrobial susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa from inpatient infections in the U.S.: 1999-2002 TRUST surveillance. Critical Care Congress, 2003, Abstract 22015.
8. Gillespie T, Masterton RG. Investigation into the selection frequency of resistant mutants and the bacterial kill rate by levofloxacin and ciprofloxacin in non-mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients. Int J Antimicrob Agents 2002;19:377-82.
9. Zhanel GG, Walters M, Laing N, Hoban DJ. In vitro pharmacodynamic modeling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2001;47:435-40.
10. Thornsberry C, Ogilvie PT, Holley HP Jr, Sahm DF. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective U.S. study. Antimicrob Agents Chemother 1999;43:2612-23.
11. Biedenbach DJ, Barrett MS, Croco MA, Jones RN. Bay 12-8039, a novel fluoroquinolone, activity against important respiratory tract pathogens. Diagn Microbiol Infect Dis 1998;31:45-50.
12. Jones RN, Pfaller MA. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance data from the Sentry antimicrobial surveillance program. Clin Infect Dis 2000;31(Suppl 2):S16-23.
13. Doern GV, Heilmann KP, Huynh HK, Rhomberg PR, Coffman SL, Brueggemann AB. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001;45:1721-9.
14. Thornsberry C, Sahm DF, Kelly LJ, Critchley IA, Jones ME, Evangelista AT, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST surveillance program, 1999-2000. Clin Infect Dis 2002;34(Suppl 1):S4-16.
15. Sahm DF, Thornsberry C, Jones ME, Blosser RS, Critchley IA, Evangelista AT, et al. Correlation of antimicrobial resistance among Streptococcus pneumoniae in the U.S.: 2001-2002 TRUST surveillance. Interscience Conference on Antimicrobial Agents and Chemotherapy, 2002, Abstract C2-1640.
16. Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 2002;62:13-59.
17. Lacey MK, Lu W, Xu X, Tessier PR, Nicolau DP, Quintiliani R, Nightingale CH. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother 1999;43:672-7.
18. Nightingale CH, Grant EM, Quintiliani R. Pharmacodynamics and pharmacokinetics of levofloxacin. Chemotherapy 2000;46 (Suppl 1):6-14.
19. Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001;45:2793-7.
20. Kolhepp SJ, Grunkemeier G, Leggett JE, Dworkin RJ, Slaughter SE, Gilbert DN. Phenotypic resistance of penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae after single and multiple in vitro exposures to ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovofloxacin. Annual Meeting Infectious Diseases Society of America, 2000, Abstract 97.
21. Klepser M, Ernst E, Petzold CR, Rhomberg P, Doem GV. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model. Antimicrob Agents Chemother 2001;45:673-8.
22. Low D, de Azavedo J, Weiss K, Mazzulli T, Kuhn M, Church D, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob Agents Chemother 2002;46:1295-301.
23. Brueggemann AB, Coffman SL, Rhomberg P, Huynh H, Almer L, Nilius A, et al. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob Agents Chemother 2002;46:680-8.
24. Evangelista AT, Loeloff M, Pfelger S, Davies T, Bush K, Mauriz Y, et al. Cross-resistance among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. J Antimicrob Chemother 2001;47 (Suppl 1):29, Abstract P50.
25. Davies TA, Pfleger S, Goldschmidt R, Bush K, Sahm DF, Evangelista AT. Characterization of U.S. clinical Streptococcus pneumoniae strains from 2000-2001 that are cross-resistant to ciprofloxacin, gatifloxacin, levofloxacin, and moxifloxacin. Annual Meeting Infectious Disease Society of America 2002, Abstract 78.
26. Davies TA, Evangelista A, Pfleger S, Bush K, Sahm DF, Goldschmidt R. Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae isolated in the United States in 1992-1996 and 1999-2000. Antimicrob Agents Chemother 2002;46:119-24.
27. Davidson R, Covalcanti R, Brunton JL, Bast DI, de Azavedo JC, Kibsey P, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346:747-50.
28. Horcajada JP, Vila J, Moreno-Martinez A, Ruiz J, Martinez J, Sánchez M, Soriano E, et al. Molecular epidemiology and evolution of resistance to quinolones in Escherichia coli after prolonged administration of ciprofloxacin in patients with prostatitis. J Antimicrob Chemother 2002;49:55-9.
29. Hoellman DB, Kelly LM, Jacobs MR, Appelbaum PC. Comparative antianaerobic activity of BMS 284756. Antimicrob Agents Chemother 2001;45:589-92.
30. Ednie LM, Jacobs, Appelbaum PC. Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms. Antimicrob Agents Chemother 1998;42:2459-62.
31. Zhanel GG, Laing NM, DeCorby M, Nichol KA, Hoban DJ. Pharmacodynamic activity of fluoroquinolones in a mixed infection simulationg an artificial bowel: effect of eradicating Bacteroides fragilis. American Society for Microbiology, 2002, Abstract A-145.